The U.S. Food and Drug Administration (FDA) issued a revised boxed warning for Tofacitinib (Xeljanz, Xeljanz XR) on 2026-07-15. This significant label change emphasizes increased risks for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. The warning specifically notes that patients treated with tofacitinib oral solution face an elevated risk for developing serious bacterial, fungal, and viral infections.
Details of the Revised Warning
The updated boxed warning for Tofacitinib consolidates and highlights several critical safety concerns. It explicitly warns of an increased risk for serious infections, including bacterial, fungal, and viral types, particularly for patients using tofacitinib oral solution. Furthermore, the revision underscores heightened risks of mortality, various malignancies, major adverse cardiovascular events, and thrombosis. These categories represent significant potential complications that healthcare providers and patients must consider.
What this means
This revision to Tofacitinib's boxed warning serves as a crucial update for clinicians, researchers, and patient advocates. For healthcare providers, it necessitates a thorough re-evaluation of the risk-benefit profile for individual patients, especially those with pre-existing conditions that might predispose them to these serious adverse events. Careful patient selection, ongoing monitoring for signs of infection, malignancy, or cardiovascular issues, and clear communication of these risks to patients are paramount. Patients currently on or considering Tofacitinib should discuss these updated warnings with their healthcare team to understand the implications for their treatment plan.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA), detailing a label revision for Tofacitinib effective 2026-07-15. The updated label is accessible via dailymed.nlm.nih.gov.